Inhalable Lactoferrin/Chondroitin-Functionalized Monoolein Nanocomposites for Localized Lung Cancer Targeting
- 21 January 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 6 (2) , 1030-1042
Abstract
Localized drug delivery to lung cancer can overcome the limitations of systemic nanocarriers including low drug amount reaching lung tissue and severe off-target toxicity. The current work presented novel inhalable nanocomposites as non-invasive platforms for lung cancer therapy. Nanoparticulate liquid crystals (LCNPs) based on monoolein were developed for synergistic co-encapsulation of the cytotoxic chemotherapeutic drug, pemetrexed and the phytoherbal drug, resveratrol (PEM-RES-LCNPs). For active tumor targeting, lactoferrin (LF) and chondroitin sulfate (CS), natural polymers with intrinsic tumor targeting capabilities, were exploited to functionalize the surface of LCNPs using layer-by-layer (LbL) self-assembly approach. To maximize their deep lung deposition, LF/CS-coated PEM-RES-LCNPs were then microencapsulated within various carriers to obtain inhalable nanocomposites via spray-drying technique. The inhalable dry powder nanocomposites prepared using mannitol-inulin-leucine (1:1:1 wt) mixture displayed superior in-vitro aerosolization performance (2.72 µm MMAD and 61.6 % FPF) which ensured deep lung deposition. In lung cancer bearing mice using urethane as a chemical carcinogen, the inhalable LF/CS-coated PEM-RES-LCNPs nanocomposites showed a superior antitumor activity as revealed by considerable decrease of average lung weight, reduced number and diameter of cancerous lung foci, decreased expression of VEGF-1 and increased expression of active caspase-3 as well as reduced Ki-67 expression compared to spray-dried free PEM/RES mixture and positive control. Moreover, in-vivo fluorescence imaging confirmed successful lung deposition of the inhalable nanocomposites. Conclusively, those inhalable liquid crystalline nanocomposites elaborated in the current work could open new avenues for non-invasive lung cancer treatment.Keywords
Funding Information
- Science and Technology Development Fund (5791)
This publication has 54 references indexed in Scilit:
- The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromoleculesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapyJournal of Controlled Release, 2013
- Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapyBiomaterials, 2012
- Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: A design of experiment approachInternational Journal of Pharmaceutics, 2011
- Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse modelJournal of Controlled Release, 2011
- Lactoferrin and cancer in different cancer modelsFrontiers in Bioscience-Scholar, 2011
- Aerosol Drug Delivery2010
- FDA Drug Approval Summary: Pemetrexed for Injection (Alimta®) for the Treatment of Non-Small Cell Lung CancerThe Oncologist, 2005
- Cancer prevention by bovine lactoferrin and underlying mechanisms — a review of experimental and clinical studiesBiochemistry and Cell Biology, 2002
- Novel Process for Producing Cubic Liquid Crystalline Nanoparticles (Cubosomes)Langmuir, 2001